Debiopharm International SA Strengthens Compliance and Clinical Trial Oversight with Veeva Vault eTMF
Veeva Systems (NYSE: VEEV) announced today that Debiopharm International SA, part of Swiss-based biopharmaceutical company Debiopharm Group™, selected Veeva Vault eTMF to improve oversight across its trial master file (TMF) processes and work closely with contract research organizations (CROs) by collaborating on a single, cloud-based application.
“Veeva is helping us streamline our clinical operations,” said Christian A. Aeschlimann, director of clinical operations at Debiopharm. “Veeva Vault eTMF will help us maintain an always-accurate, up-to-date TMF and align with external partners by working in the same system.”
As a sponsor, Debiopharm is required by ICH E6(R2) to maintain oversight throughout clinical trials. External partners were unable to access the company's previous, on-premise eTMF, so CROs used their own systems and transferred documents periodically. This meant that Debiopharm did not have full, real-time visibility into the CROs’ TMF activities.
Veeva Vault eTMF provides a single source of truth for trial documentation. Sponsors and CROs can manage TMF documents and processes in the same system, in real-time, as they are being executed. Now Debiopharm can keep its TMF in a constant state of inspection readiness and ensure partners adhere to its standard operating procedures.
“In our quest for continuous improvement, we selected Veeva Vault eTMF to help us work more efficiently and maintain high quality trial documentation,” said Vincent Demeautis, clinical operations manager at Debiopharm. “Sharing a single system with CROs to drive all TMF processes will eliminate the need to manage and reconcile multiple TMF sources while improving our responsiveness and collaboration with external and internal study team members.”
Veeva Vault eTMF will also provide Debiopharm with reports and dashboards for visibility into TMF completeness, timeliness, and accuracy. This will help the company to check the status and quality of documentation and proactively resolve any issues that arise.
"Veeva Vault eTMF was the best solution on the market to meet our current and future needs," said Sofie Lemmens, senior clinical trial associate at Debiopharm, who led the implementation of Veeva Vault eTMF. "It was a critical investment across our internal teams to improve TMF quality and access."
By adopting Veeva Vault eTMF, Debiopharm has taken its first step toward a unified clinical model to streamline end-to-end processes and systems, increase collaboration, and improve performance across trials. This reflects an industrywide shift, with nearly all (99%) respondents to the Veeva 2017 Unified Clinical Operations Survey reporting the need to unify their clinical operations.
“Sponsors are unifying systems and processes to improve study quality and execution while managing a growing number of trials and increasing complexity across the clinical lifecycle,” said Rik Van Mol, vice president, R&D Strategy, Europe at Veeva. “Veeva Vault eTMF lets Debiopharm improve trial visibility and compliance as well as begin a journey toward unified clinical operations.”
Veeva Vault eTMF is part of Veeva Vault Clinical Suite, the industry's first suite of applications that combines eTMF with EDC, CTMS, and study start-up to unify clinical data management and operations. To learn how organizations are eliminating system silos across clinical operations with Veeva Vault Clinical Suite, visit veeva.com/eu/Clinical.
For more on Veeva Vault eTMF, visit: veeva.com/eu/eTMF
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 600 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com/eu.
About Debiopharm International SA
Part of Debiopharm Group™ – a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management – Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. For more information, please visit debiopharm.com or follow @DebiopharmNews on Twitter.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-K for the period ended January 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
Veeva Systems Inc.
+44 (0) 7715 817589
+44 (0) 7746 546773
Debiopharm International SA
Christelle von Büren
+41 (0)21 321 01 11
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Greene Tweed Receives Patent for Rapid Gas Decompression-Resistant Fluoroelastomers and Molded Articles24.10.2018 00:00 | Tiedote
The U.S. Patent Office has awarded Greene Tweed Patent Number 10,011,690 for Rapid Gas Decompression-Resistant Fluoroelastomer Compositions and Molded Articles. The innovative elastomer technology was developed by a team that included inventor Ron Campbell, PhD, Principal Scientist and Technology Leader for Elastomers in Greene Tweed’s Advanced Technology Group, to provide a competitive advantage in the Energy market and expand technology protected under a previous patent. Rapid gas decompression (RGD) often occurs when high-pressure gas molecules migrate into an elastomer at a compressed state. When the pressure surrounding the elastomer is suddenly released, the compressed gas inside the elastomer tries to expand and exit the elastomer, thus causing RGD (also known as explosive decompression). Most elastomers experience severe blistering or cracking when the force of these expanding gases overcome the strength of the surrounding material; however, materials engineered to withstand RG
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains23.10.2018 21:00 | Tiedote
Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting good health outcomes. The results of a new study strengthen the evidence for this theory, showing that infant-type HRB may be able to break down incompletely digested peptides in the infants’ gastrointestinal systems and thus contribute to their overall health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005015/en/ Fig 1. Food-derived opioid peptides are potential risk factors for human health (Graphic: Business Wire) Human-Residential Bifidobacteria for Humans Morinaga Milk has been conducting research on bifidobacteria for many years, and studies over the past decades have shown that bifidobacteria play a vital role in various aspects of human health. There are two major groups of bifidobacteria: Human-Residential Bif
myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris23.10.2018 19:22 | Tiedote
Christo Georgiev, fintech entrepreneur and founder of myPOS, has confirmed his intention to open two new flagship stores in major European cities by the end of the year. The opening is part of an initiative to bring the product closer to potential customers, giving them a hands-on experience and a live demonstration of what myPOS has to offer. The two new stores will be opened in Barcelona, Spain and Paris, France – two of the most important markets for myPOS. “Our Spanish and French customers have always placed a tremendous amount of trust in us, and we in turn have worked hard to justify it,” Georgiev says. “Opening physical locations in Barcelona and Paris is an extension of that relationship. It’s important to test a product with your own hands before you choose to trust it, and if that’s true for TVs and phones why can’t it apply to POS terminals?” The Barcelona store will open as soon as November, followed shortly by the Paris one before the end of the year. myPOS has already ope
Christo Georgiev Announces the Arrival of myPOS AppMarket23.10.2018 19:11 | Tiedote
myPOS Europe Ltd., a leading card payments provider to small and medium-sized businesses in Europe, is introducing its own AppMarket – an innovative software platform for business applications that allows myPOS clients to find, download and use various apps for improved business performance. The development of myPOS AppMarket was driven by the necessity to meet the ever-changing business needs dictated by customer demand and behaviour. While the payment terminals myPOS offers come with a large number of innovative payments features, there are other business needs which remain uncaptured at the moment. myPOS founder Mr. Christo Georgiev says: “Individual businesses need a tailored approach when it comes to accepting payments for their services. Offering a fully customizable and complete omni-channel payments solution, which empowers businesses to stay agile, has always been in our foresight. Tapping into the familiarity of our everyday favourite device – the smartphone, pushed us even f
CNIM Presents a Rapid Version of The LCAT® Shore-to-Shore Featuring Unique Operational Capabilities23.10.2018 18:45 | Tiedote
The L-CAT® Shore-to-shore presented by CNIM at Euronaval 2018 delivers a major increase in performance for amphibious missions. The L-CAT® Shore-to-shore has been upgrated since its launch 2 years ago. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005869/en/ CNIM's amphibious craft, the L-CAT® Shore-to-shore (Photo: CNIM) The L-CAT® Shore-to-shore is now the only vessel with the ability to transport 80 tonnes at 25 knots in conditions up to sea state 5, land in shallow water (~1m) and accommodate 42 passengers for long distance trips. Highly maneuvrable, the L-CAT® Shore-to-shore provides exceptional operational flexibility for amphibious assaults and humanitarian operations, without compromising between speed and payload. Its wide loading platform (145 m²), ability to travel up to 800 nautical miles when loaded, self-defence and communication capabilities are tactical advantages for the projection of Forces. Its spee
Exterior Plus, a Portfolio Company of H.I.G. Capital, Acquires Impactmedia23.10.2018 16:03 | Tiedote
Exterior Plus, the out-of-home advertising platform of H.I.G. Capital, announces the acquisition of Impactmedia (the “Company”), a leading shopping mall advertising company, with over 630 million viewers in high-traffic premium locations throughout Spain. This is a major step forward in Exterior Plus’s consolidation strategy, as it aims to become the Spanish leader in out-of-home advertising with a unique, diversified and highly-competitive product portfolio, reaching very diverse audiences at a national level. Impactmedia is an experienced leader in shopping mall advertising, offering digital advertising as well as special marketing actions. The Company operates in over 90 shopping centers where it has more than 1,200 digital displays. The acquisition allows Exterior Plus to gain a strong presence near points of sale, a key value driver for advertisers. H.I.G. Capital acquired and established the Exterior Plus group in December 2015. The group currently markets more than 25,000 advert
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme